Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds for the treatment of a broad range of life-threatening or debilitating rare diseases through the inhibition of the complement system at the level of C3. Apellis was founded in 2008 with a dedicated focus to boldly control C3, and is the first company to advance chronic therapy with a C3 inhibitor into clinical trials.
Apellis is committed to improving the lives of patients impacted by rare diseases and will proudly be showing its stripes all month and on Rare Disease Day 2019, February 28.
